Page 7 - Nasdaq Bmea News Today

Biomea Fusion (NASDAQ: BMEA – Get Rating) is one of 929 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Biomea Fusion to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, risk, profitability and valuation. Profitability This table compares Biomea […]

Shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) have received an average recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price objective […]

BMF-219 displays global disruption of menin, highlighting ‘219’s novel mechanism of actionMolecule elicits broad impact on the complexes surrounding menin,...

Biomea Announces Pricing of Initial Public Offering April 15, 2021 22:32 ET | Source: Biomea Fusion, Inc, Biomea Fusion, Inc, Redwood City, California, UNITED STATES REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically define...